Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 215-224

  Shearman, Lauren P ^a   Stribling, D Sloan ^a   Camacho, Ramon E ^a   Rosko, Kimberly M ^a   Wang, Junying ^a   Tong, Sharon ^a   Feng, Yue ^a   Marsh, Donald J ^a   Yu, Hong ^a   Guan, Xiaoming ^a   Spann, Stephanie K ^a   MacNeil, Douglas J ^a   Fong, Tung M ^a   Metzger, Joseph M ^a   Goulet, Mark T ^a   Hagmann, William K ^a   Plummer, Christopher W ^a   Finke, Paul E ^a   Mills, Sander G ^a   Shah, Shrenik K ^a   Truong, Quang ^a   Van der Ploeg, L H T ^a   MacIntyre, D Euan ^a   Strack, Alison M ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adiposity; Body weight; Cannabinoid; Diet induced obesity; Food intake; Obesity

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLOROPHENYL) N CYCLOHEXYL 4 (2,4 DICHLOROPHENYL) 1 METHYLIMIDAZOLE 2 CARBOXAMIDE; BRAIN RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLIC AMP; DEXFENFLURAMINE; FORSKOLIN; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BODY COMPOSITION; C57BL 6 MOUSE; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; EX VIVO STUDY; FOOD INTAKE; HYPOTHERMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SPRAGUE DAWLEY RAT; TREATMENT DURATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; AUTORADIOGRAPHY; BRAIN; DEXFENFLURAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; EATING; HUMANS; IMIDAZOLES; MALE; MICE; MICE, KNOCKOUT; OBESITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 37549028863     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.033     Document Type: Article

References (42)

1. Abel E. Cannabis: effects on hunger and thirst. Behav. Biol. 15 (1975) 255-281
2. Arnone M., Maruani J., Chaperon F., Thiebot M., Poncelet M., Soubrie P., and Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl.) 132 (1997) 104-106
3. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J., Le Fur G., Oury-Donat F., and Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63 (2003) 908-914
4. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., and Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312 (1995) 637-641
5. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.-P., Le Fur G., and Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor. J. Biol. Chem. 272 (1997) 22330-22339
6. Breivogel C., Griffin G., Di Marzo V., and Martin B. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60 (2001) 155-163
7. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., and Gessa G. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63 (1998) PL113-PL117
8. Cosenza M., Gifford A., Gatley S., Pyatt B., Liu Q., Makriyannis A., and Volkow N. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 38 (2000) 477-482
9. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G., Pasquali R., and Pagotto U. Endogenous cannabinoid system as a modulator of food intake. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 289-301
10. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C.E., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112 (2003) 423-431
11. Devane W., Hanus L., Breuer A., Pertwee R., Stevenson L., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1882-1884
12. Di Marzo V., Goparaju S., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G., Palmiter R., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
13. Fitton A., and Pertwee R. Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. Br. J. Pharmacol. 75 (1982) 409-414
14. Foltin R., Fischman M., and Byrne M. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11 (1988) 1-14
15. Fruebis J., Tsao T., Javorschi S., Ebbets-Reed D., Erickson M., Yen F., Bihain B., and Lodish H. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2005-2010
16. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995) 54-61
17. Hildebrandt A., Kelly-Sullivan D., and Black S. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur. J. Pharmacol. 462 (2003) 125-132
18. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35 (1995) 607-634
19. Jamshidi N., and Taylor D. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 134 (2001) 1151-1154
20. Jarai Z., Wagner J., Varga K., Lake K., Compton D., Martin B., Zimmer A., Bonner T., Buckley N., Mezey E., Razdan R., Zimmer A., and Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 14136-14141
21. Kirkham T., Williams C., Fezza F., and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136 (2002) 550-557
22. Liu Y., Connoley I., Wilson C., and Stock M. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. (Lond). 29 (2005) 183-187
23. Martin B., Compton D., Thomas B., Prescott W., Little P., Razdan R., Johnson M., Melvin L., Mechoulam R., and Ward S. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40 (1991) 471-478
24. Masaki T., Chiba S., Yasuda T., Tsubone T., Kakuma T., Shimomura I., Funahashi T., Matsuzawa Y., and Yoshimatsu H. Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. Diabetes 52 (2003) 2266-2273
25. Matsuda L., Lolait S., Brownstein M., Young A., and Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
26. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N., Schatz A., Gopher A., Almog S., Martin B., Compton D., Pertweee R., Griffine G., Bayewitchf M., Bargf J., and Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Br. J. Pharmacol. 50 (1995) 83-90
27. Munro S., Thomas K., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
28. Need A., Davis R., Alexander-Chacko J., Eastwood B., Chernet E., Phebus L., Sindelar D., and Nomikos G. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology (Berl.) 184 (2006) 26-35
29. Pi-Sunyer F.X., et al., for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
30. Plummer C., Finke P., Mills S., Wang J., Tong X., Doss G., Fong T., Lao J., Schaeffer M., Chen J., Shen C., Stribling D., Shearman L., Strack A., and Van der Ploeg L. Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. Bioorg. Med. Chem. Lett. 15 (2005) 1441-1446
31. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J., and Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol., Regul. Integr. Comp. Physiol. 284 (2003) R345-R353
32. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., and Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 640-648
33. Rawls S.M., Cabassa J., Geller E.B., and Adler M.W. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia. J. Pharmacol. Exp. Ther. 301 (2002) 963-968
34. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J., and Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
35. Simiand J., Keane M., Keane P., and Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. 9 (1998) 179-181
36. Vickers S., Webster L., Wyatt A., Dourish C., and Kennett G. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl.) 167 (2003) 103-111
37. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
38. Wang L., Liu J., Harvey-White J., Zimmer A., and Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1393-1398
39. Westlake T., Howlett A., Bonner T., Matsuda L., and Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63 (1994) 637-652
40. Williams C., and Kirkham T. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl.) 143 (1999) 315-317
41. Williams C., and Kirkham T. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol. Biochem. Behav. 71 (2002) 333-340
42. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 5780-5785